This article summarizes published peptide research. All content is presented for research reference only and is not intended as medical advice or guidance for personal peptide use. Products referenced are research compounds — not for human consumption, diagnostic or therapeutic application.

Fat burning and weight loss are different processes often confused. Weight loss means reducing body mass — including water, glycogen and muscle. Fat burning is targeted oxidation of triglycerides from adipose tissue while preserving metabolically active muscle. A classic caloric deficit delivers 0.5–fat-metabolism effects per week, but after 3–4 months metabolism adapts and the plateau becomes unbeatable. Fat-burning peptides work not through appetite suppression but directly — triggering lipolysis, accelerating mitochondrial beta-oxidation and activating brown adipose thermogenesis. At PEPTEX we see this approach producing results without the yo-yo effect.

Fat burning vs weight loss — the difference

The scale shows total mass, not body composition. A 5 kg loss can include 2 kg fat, 1.5 kg muscle and 1.5 kg water, dropping basal metabolism by 80–120 kcal/day. Fat burning focuses on reducing adipose tissue (measured by % body fat via DEXA or BIA), while muscle is preserved or even grows. Peptide protocols are therefore judged not only by kilograms but by waist circumference, muscle/fat ratio, and biomarkers — leptin, adiponectin, fasting insulin.

An important marker of quality fat loss is reduction of visceral fat, directly tied to cardiovascular risk. Tesamorelin and GLP-1 agonists lead on this parameter. See our GLP-1 weight loss guide for deeper analysis.

Three biochemical pathways: lipolysis, beta-oxidation, thermogenesis

Fat burning is a three-step chain; failure at any stage nullifies the process. Lipolysis breaks triglycerides into free fatty acids (FFA) and glycerol via hormone-sensitive lipase (HSL) and ATGL. Triggered by catecholamines, GH, and peptides like AOD-9604 through beta-3 adrenergic receptors (PubMed 22584800). Beta-oxidation transports FFAs into mitochondria via the carnitine shuttle, breaking them down to acetyl-CoA feeding the Krebs cycle, regulated by AMPK and mitochondrial density (PubMed 21487133). Thermogenesis converts chemical energy into heat in brown fat via UCP1, activated by cold, caffeine and tesamorelin.

Why diets plateau

After 3–4 months of deficit, leptin drops 40–60%, T3 falls 20–30%, resting metabolism slows 5–10%. This is adaptive thermogenesis. Peptides bypass these mechanisms: AOD-9604 drives lipolysis directly; MOTS-C activates AMPK and renews mitochondria.

The insulin resistance factor

High fasting insulin blocks HSL and halts lipolysis. Dropping fasting insulin from 15 to 6 µU/ml doubles overnight fat burning. MOTS-C and 5-Amino-1MQ help here.

AOD-9604 — a classic GH fragment for lipolysis

AOD-9604 is a synthetic peptide representing the C-terminal fragment (amino acids 177–191) of growth hormone with an added tyrosine. Developed in the early 2000s as an anti-obesity drug. Unlike full GH, AOD-9604 does not raise IGF-1, cause fluid retention, or affect glucose while retaining lipolytic activity (PubMed 11602048).

In a 12-week phase 2 trial, AOD-9604 1 mg/day produced 2.6x more weight loss than placebo, primarily from abdominal fat (PubMed 17956598). Practical protocol: 300 mcg subcutaneous, fasted morning, 30 min before cardio, 5–6 days/week, 8–12 week cycle. Expected outcome: 3–fat-metabolism effects with muscle preservation.

Receptor-level mechanism

AOD-9604 upregulates beta-3 adrenergic receptor expression in adipocytes by 40–60%, sensitizes HSL to catecholamines and raises baseline lipolysis 2–3x.

Best fit profiles

Athletes cutting, individuals with stubborn abdominal fat post-diet, clients 35+ with declining GH. See our honest AOD-9604 review and AOD-9604 vs tirzepatide comparison.

Parameter	AOD-9604	Full GH
Lipolysis	Yes, strong	Yes
IGF-1 rise	No	Yes (cancer risk)
Water retention	No	Yes
Glucose effect	Neutral	Elevates
Side effects	Minimal	Multiple
Cycle cost	Moderate	High

MOTS-C — mitochondrial peptide, AMPK activator

MOTS-C (Mitochondrial Open Reading frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded by mitochondrial DNA, discovered in 2015 by Lee and colleagues (PubMed 25738459). Its main function is AMPK activation — the cell's metabolic master switch, toggling from energy storage to expenditure (PubMed 26626483).

Practically: MOTS-C increases insulin sensitivity by 25–40%, boosts muscle fatty acid beta-oxidation, stimulates mitochondrial biogenesis (PGC-1α). Protocol: 5–10 mg subcutaneous 2–3x/week, 8–12 week cycle. Expected: 2–fat-metabolism effects, endurance gains, HbA1c drop of 0.3–0.5%. Deep-dives: MOTS-C and metabolism and mitochondria-aging connection.

5-Amino-1MQ — NNMT inhibitor

5-Amino-1-methylquinolinium is a small molecule inhibiting nicotinamide-N-methyltransferase (NNMT), which is expressed 2–3x higher in obese adipose tissue. Blocking NNMT raises NAD+ in adipocytes and increases energy expenditure (PubMed 29773825).

In mouse models 5-Amino-1MQ reduced body mass by 14% with no diet change. In practice: 50–150 mg oral daily morning, 8–12 week cycle. Selectivity for adipose tissue without muscle impact. Pairs well with AOD-9604.

Tesamorelin for visceral fat

Tesamorelin is a stabilized GHRH analog (44 amino acids) stimulating pituitary GH release. FDA-approved for HIV-associated visceral fat and widely used in metabolic practice.

In phase 3, tesamorelin 2 mg/day for 26 weeks reduced visceral fat by 15.2% (PubMed 19734430). Meta-analysis confirms a sustained 15–20% reduction with lipid profile improvement (PubMed 27416104). Protocol: 1–2 mg evening subcutaneous, 5 days/week, 12–26 week cycle. Details in tesamorelin vs CJC-1295 and ipamorelin + tesamorelin stack.

GLP-1 peptides for fat burning — their role

GLP-1 agonists — tirzepatide, semaglutide, retatrutide — reduce body mass 15–22.5% in 68–72 weeks via appetite suppression and gastric emptying delay (PubMed 33567185, PubMed 35658024). But 25–40% of lost mass is muscle. Adjunct direct fat-burning peptides — AOD-9604 and MOTS-C — protect muscle and enhance fat-specific oxidation.

Full breakdown in the GLP-1 guide, tirzepatide vs retatrutide in a dedicated comparison, and muscle/skin protection on GLP-1 in GHK-Cu + GLP-1.

Comparative table of fat-burning peptides

Peptide	Mechanism	Fat loss (12w)	Appetite	Visceral fat	Cost
AOD-9604	Lipolysis via B3-AR	3–5%	Neutral	Moderate	$$
MOTS-C	AMPK / mitochondria	2–4%	Neutral	Moderate	$$
5-Amino-1MQ	NNMT inhibitor	3–5%	Neutral	Moderate	$$$
Tesamorelin	GHRH / GH rise	5–8% (visc.)	Neutral	Strong	$$$
Tirzepatide	GLP-1 / GIP	15–20%	Strong suppression	Strong	$$$$
Retatrutide	GLP-1/GIP/glucagon	notable magnitudes.5%
Post-GLP-1 plateau	AOD-9604 + tesamorelin	12 weeks	-3–5% fat at plateau
Longevity + composition	MOTS-C + epithalon + NAD+	16 weeks	-3–4% fat, mitochondria

See the Read more: Fat Metabolism: Peptide Research Protocols — PEPTEX Research